SPG20 Antibody | 18-028

SPG20 Antibody | 18-028 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse, Rat

Homology: N/A

Immunogen: Recombinant fusion protein containing a sequence corresponding to amino acids 1-350 of human SPG20 (NP_055902.1) .

Research Area: Other

Tested Application: WB

Application: WB: 1:500 - 1:2000

Specificiy: N/A

Positive Control 1: K-562

Positive Control 2: HeLa

Positive Control 3: 293T

Positive Control 4: Mouse liver

Positive Control 5: Mouse heart

Positive Control 6: Mouse brain

Molecular Weight: Observed: 73kDa

Validation: N/A

Isoform: N/A

Purification: Affinity purification

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

Concentration: N/A

Storage Condition: Store at -20˚C. Avoid freeze / thaw cycles.

Alternate Name: SPARTIN, trans-activated by hepatitis C virus core protein 1, spastic paraplegia 20, spartin (Troyer syndrome) , OTTHUMP00000018254, TAHCCP1, SPARTIN, KIAA0610, spastic paraplegia 20 (Troyer syndrome) , SPG20

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: This gene encodes a protein containing a MIT (Microtubule Interacting and Trafficking molecule) domain, and is implicated in regulating endosomal trafficking and mitochondria function. The protein localizes to mitochondria and partially co-localizes with microtubules. Stimulation with epidermal growth factor (EGF) results in protein translocation to the plasma membrane, and the protein functions in the degradation and intracellular trafficking of EGF receptor. Multiple alternatively spliced variants, encoding the same protein, have been identified. Mutations associated with this gene cause autosomal recessive spastic paraplegia 20 (Troyer syndrome) . [provided by RefSeq, Nov 2008]